Replies to post #63 on Immatics NV (IMTX)

[FACT-MASTER]

I concur with that analysis.

What i find interesting is that they reported interim clinical data on IMA203 on October 10/22
https://ih.advfn.com/stock-market/NASDAQ/immatics-nv-IMTX/stock-news/89257173/immatics-reports-interim-clinical-data-update-on-a

but held back the data on IMA203 + checkpoint inhibitor and IMA203CD8 - pushing the release of that data into 2023:

"we are awaiting data from two additional dose expansion cohorts: IMA203 together with an immune checkpoint inhibitor and our 2nd generation product candidate IMA203CD8. As we continue to shift our focus from Phase 1a to Phase 1b, we look forward to reporting meaningful data throughout 2023, "

Then the capital raise at $10.09 on the same day Oct.10/22

https://ih.advfn.com/stock-market/NASDAQ/immatics-nv-IMTX/stock-news/89257170/immatics-announces-110-million-underwritten-offer

Is it just my imagination, or could the sequence of events ( IMA203 limited clinical data Oct.10/22 - capital raise Oct.10/22 - GSK cutting ties with Lyell and Adaptimmune Oct.25/22) indicate that some positive to very positive news is afoot (IMA203 checkpt. , IMA203CD8) with IMTX?

GSK maybe taking a bigger position before the wildly amazing news is released in 2023 - just speculating a little, because imo, the stock is acting as though big buyers are accumulating.